When Zero Isn’t Zero

If a doctor has ever told you or your partner that a semen analysis came back with no sperm, you already know how final that sentence can feel. Azoospermia can feel less like a diagnosis and more like a verdict. Most people leave that appointment believing the biological question is settled.

It turns out that this diagnosis has always carried more uncertainty than it lets on. And in the last year, a set of new tools has started to make that uncertainty visible in a way that could change what happens after a man hears it.

Below, we get into what azoospermia actually means, why “zero” was never quite as absolute as it sounded, and what the arrival of AI-assisted sperm detection does (and does not) change. This is a story about male-factor infertility, which accounts for roughly 40% of infertility cases, and about a corner of medicine that has spent a long time in the shadows.

Azoospermia means that when a semen sample is examined under a microscope, no sperm are found in the ejaculate. It shows up in about 10 to 15% of men with infertility, and roughly 1% of all men. That is not a rare footnote; it is a meaningful slice of the people sitting in fertility clinics, often after their partner has already been through an extensive workup.

The word covers two very different situations. In obstructive azoospermia, the testes are making sperm, but a blockage keeps them from reaching the ejaculate. In non-obstructive azoospermia, the harder case, the testes are producing very little sperm, or producing it only in scattered pockets of tissue. The AUA/ASRM male infertility guideline treats these as distinct diagnoses with distinct paths, which matters, because the second kind is where the word “zero” has always been most misleading.

Here is the part that rarely gets explained in the room: a standard semen analysis looks at a small droplet, not the entire sample. “No sperm found” has always meant “none found in what we examined,” which is not the same as “none exist anywhere.” For men with non-obstructive azoospermia, sperm can still be hiding in the testicular tissue, or present in the ejaculate in numbers so small that a routine scan sails right past them.

The myth: “Azoospermia means there is no possibility of a biological child.”

The reality: For many men, especially those with the non-obstructive type, sperm can often still be found, either surgically in the testes or, increasingly, by looking at the ejaculate far more carefully than a standard analysis allows. As Dr. Zev Williams of Columbia University put it, “you only need one healthy sperm to create an embryo.”

Until recently, the main answer to non-obstructive azoospermia was a surgery called micro-TESE (microdissection testicular sperm extraction). A surgeon uses an operating microscope to search through testicular tissue, looking for the healthiest tubules and the sperm they might contain. When it works, it can be the difference between a biological child and none. It is genuinely one of the important advances in male fertility care.

But it is worth being clear-eyed about what it asks of patients. Micro-TESE is a real operation, with anesthesia, recovery, and cost. And even in experienced hands, it does not always succeed: sperm retrieval rates in non-obstructive azoospermia generally land somewhere around 40 to 60%, depending heavily on the underlying cause and the center performing it. That means a substantial number of men go through surgery and still come out the other side with no sperm found. For a diagnosis that already carries so much weight, that uncertainty is a lot to hold.

This is where the last year gets interesting. Instead of asking a person to search a sample by eye, or a surgeon to search by hand, researchers have started training artificial intelligence to do the looking, at a scale no human can match.

The most talked-about example is a system called STAR, for Sperm Tracking and Recovery, developed over about five years by Dr. Zev Williams and a team at the Columbia University Fertility Center. The inspiration came from an unlikely place: the imaging techniques astronomers use to pick out faint stars and planets against a huge dark sky. Applied to a semen sample, the same idea means scanning enormous numbers of images very fast. STAR can capture and search more than eight million images in about an hour, and when it spots a sperm cell, a microfluidic chip gently routes that tiny portion of fluid away to be collected.

The numbers from early demonstrations are striking. In one case reported by TIME, technicians who searched a sample by hand for two days found nothing; STAR found dozens of sperm in about an hour. “I liken it to finding a needle hidden within a thousand haystacks,” Williams said. “But it can do that in a couple of hours.”

In 2025, the team reported the first pregnancy achieved with the method, later documented in The Lancet. And 2026 has brought more of the same direction of travel: the July roundup from ASRM’s Fertility and Sterility journals highlighted AI-assisted imaging that identified ultrarare sperm in nearly half of samples previously classified as azoospermic, prompting researchers to float a new term, “microzoospermia,” for these extremely low but not truly absent concentrations. The vocabulary itself is starting to catch up to a reality clinicians have long suspected: zero is often not quite zero.

Want to hear it from the source: CNN’s report “A couple tried for 18 years to get pregnant. AI made it happen” walks through how STAR works and follows one couple’s story. A clear, human introduction to the technology, about 6 minutes.

The reason this research broke out of medical journals and into the news was a single family. A woman named Rosie and her husband had been trying to conceive for close to two decades, through 15 unsuccessful IVF cycles, before the STAR method recovered a small number of viable sperm from a sample in which none had been found by hand. Those cells were used to create embryos, and in early 2025 they became the first pregnancy conceived this way.

It is a genuinely moving story, and it is also worth holding gently. One pregnancy is a beginning, not a guarantee, and the couples for whom this becomes routine are still being counted. But it makes something concrete that can otherwise sound abstract: the gap between “none found” and “none there” is where a family can sometimes live.

The AI sperm-detection story is real and promising. It is also very new, and the marketing around fertility technology has a long history of running ahead of the evidence.

A few things are worth keeping in mind. The published pregnancy results so far rest on a small number of cases, with larger clinical trials still underway. The technology is not yet widely available, and where it exists, it is offered at a limited number of centers. Detecting a sperm cell is also not the same as a live birth; those cells still have to fertilize an egg, become a viable embryo, and result in a healthy pregnancy, each of which has its own odds. And a broader lesson from the last year of fertility research applies here too: a June 2026 study found that many costly IVF add-ons fail to show real benefit. New is not automatically better, and a promising tool deserves the same scrutiny as an established one.

If you or your partner has been told a sample showed no sperm, you are allowed to ask for more detail before you accept the conversation as finished. A few questions that can open it back up:

1.     Which kind of azoospermia is this? Obstructive and non-obstructive have very different causes and options. It is a fair first question.

2.     Have we done the full workup? Guidelines call for hormone testing, a repeat semen analysis, and sometimes genetic testing before conclusions are drawn. Was anything skipped for speed?

3.     Is surgical sperm retrieval, like micro-TESE, an option for us? And what sperm-retrieval rates does this specific surgeon or center see for a case like ours?

4.     Are advanced sperm-detection methods available anywhere we can reach? AI-assisted approaches are still emerging and not everywhere, but it is reasonable to ask what exists and whether a referral makes sense.

5.     What would you do if this were your family? Sometimes the most useful question is the most human one.

The field is moving quickly, and the language is still settling. Terms like “microzoospermia” are being proposed precisely because the old binary, sperm or no sperm, was never fine enough to describe what is actually there. For the men who have carried a diagnosis of “zero” as if it were the end of the conversation, that shift matters. It does not promise anyone a specific outcome. It just reopens a question that a lot of people were told to stop asking.

If you are in the middle of this, you do not have to decide today what any of it means for you. The research will keep unfolding, and so will your options. What is worth carrying out of this piece is smaller and steadier than a headline: a result that reads as final is often the start of a more precise question, and you are allowed to keep asking it.

AUA/ASRM Male Infertility Guideline. The authoritative clinical guidance on diagnosing and treating male infertility, including azoospermia.

Columbia University Fertility Center: first pregnancy with AI-guided sperm recovery. The primary announcement of the STAR method and its first reported pregnancy.

TIME: Doctors Report the First Pregnancy Using a New AI Procedure. An accessible overview with quotes from the researchers.

ASRM Fertility and Sterility, July 2026 roundup. Recent research including the AI imaging findings behind the “microzoospermia” discussion.

CNN: A couple tried for 18 years to get pregnant. AI made it happen. The human story behind the science.

Path to Parenthood publishes journalism and education, not medical advice. Everything here is meant to inform the questions you bring to your own care team, not replace their guidance for your specific situation.